Synergy of NVP-BEZ235 and enzastaurin in mantle cell lymphoma
DOI:
https://doi.org/10.7175/cmi.v8i1.889Keywords:
Lymphoma, PI3K signaling pathway, Innovative therapyAbstract
Mantle cell lymphoma (MCL) is a neoplasm classified as a B-cell malignancy, that accounts for approximately 3 to 8% of Non-Hodgkin’s lymphoma (NHL) cases diagnosed annually. MCL is difficult to treat and seldom considered cured. The pathobiology of MCL is complex and includes alteration in the cell cycle, abnormalities in the DNA damage response, and constitutive activation of key antiapoptotic pathways including phosphatidyl-inositol 3-kinase (PI3K)/Akt and nuclear factor-kB. This has promoted the identification of new targeted treatments and new agents that have shown promising efficacy for future MCL therapies. The phosphatidylinositol 3-kinase (PI3K) mammalian target of rapamicin (mTOR) pathway mediates proliferation, survival, and drug resistance in lymphoma cells. NVP-BEZ235 (BEZ235) is a new, orally bioavailable inhibitor of PI3K and mTOR and a representative of a new class of anti-tumour agents.
In this study, we analysed the in vitro inhibitory effects of NVP-BEZ235 on mantle lymphoma cell lines (GRANTA-519 and JeKo-1) and its effects in combination with enzastaurin, everolimus and perifosine. Our data suggest that in mantle lymphoma cell lines, BEZ235 in combination with enzastaurin elicits its antitumour effect better than combined with perifosine and everolimus. Our data reveal that the drug combination targets phosphorylation of PI3K/Akt/mTOR pathways and induces both intrinsic and extrinsic apoptosis pathways. Furthermore, inhibition of Bcl-2 anti-apoptosis family members may, in part, explain the efficacy of signalling blockade in lymphoma cells and suggests an additional therapeutic targeting strategy. Therefore, these preclinical data support the potential use of BEZ235 in patients with mantle lymphoma, and in particular provide rationale for combination with enzastaurin.
References
Katso R, Okkerhaug K, Ahmadi K et al. Cellular function of PI3k: implications for development, homeostasis and cancer. Annu Rev Cell Dev Biol 2001, 17:615-675.
Reeder CB, Ansell SM. Novel therapeutic agents for B-cell lymphoma: developing rational combinations. Blood. 2011;117:1453-62
Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005 Dec;5(12):921-9
Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606-619
Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R,Driscoll PC, Woscholski R, Parker PJ, Waterfield MD: Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001, 70:535-602.
Fruman DA, Meyers RE, Cantley LC: Phosphoinositide kinases. Annu Rev Biochem 1998, 67:481-507.
Wymann MP, Pirola L: Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta 1998, 1436:127-150.
Liu P, Cheng H, Roberts TM, et al., Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Disc. 2009; 8: 627.
Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding.. Nat Rev Mol Cell Biol. 2012
Pileri SA, Falini B, Mantle cell lymphoma. Haematologica. 2009; 94: 1488-92.
Lenz G, Staudt LM, Aggressive lymphoma. New Engl J Med 2010; 362: 1417-1429.
Nogai H, Dörken B, Lenz G, Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol. 2011; 29: 1803-11.
Tchakarska G, Le Lan-Leguen A, Roth L, et al., The targeting of the sole cyclin D1 is not adequate for mantle cell lymphoma and myeloma therapies. Haematologica. 2009; 94:1781-2.
Kimura Y, Sato K, Arakawa F, et al., Mantle cell lymphoma shows three morphological evolutions of classical, intermediate, and aggressive forms, which occur in parallel with increased labeling index of cyclin D1 and Ki-67. Cancer Sci. 2010; 101: 806-812.
Wang M, Sun L, Qian J, et al., Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 2009; 23: 1320-8.
Sander B, Mantle cell lymphoma: recent insights into pathogenesis, clinical variability and new diagnostic markers. Semin Diagn Pathol. 2011; 28: 245-55.
Pérez-Galán P, Dreyling M, Wiestner A, Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011; 117: 26-38.
Alinari L, Christian B and Baiochhi RA, Novel targeted therapies for mantle lymphoma. Oncotarget 2012; 3: 203-211
Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3: 185-197.
Parekh S, Weniger MA, Wiestner A, et al., New molecular targets in mantle cell lymphoma. Semin Cancer Biol. 2011; 21: 335-46.
Smith MR, Mantle cell lymphoma: advances in biology and therapy. Curr Opin Hematol. 2008; 15: 415-21.
O’Connor OA, Moskowitz C, Portlock C, et al., Patients with chemotherapy refractory mantle cell lymphoma experience high response rates and identical progression free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicenter phase 2 clinical trials. Br J Haematol 2009; 145: 34-39.
Dunleavi K, Pittaluga S, Czuczman MS, et al., Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009; 113: 6069-6076.
Witzig TE, Reeder CB, LaPlant BR, et al., A phase 2 trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011; 25: 341-7.
Ghobrial IM, Gertz M, LaPlant BR, et al., Phase 2 trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28: 1408-1414.
Johnston PB, Inwards DJ, Colgan JP, et al., A phase 2 trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85: 320-324.
Maira SM, Stauffer F, Brueggen J, et al., Identification and development of NVP-BEZ235, a new orally available dual PI3K/mTOR inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008; 7: 1851–1863.
Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008; 68: 8022–8030.
Chapuis N, Tamburini J, Green AS, et al., Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res. 2010; 16: 5424-3.
Maira SM, Stauffer F, Brueggen J, et al., Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008; 7:1851-63.
Bhende PM, Park SI, Lim MS, et al., The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia. 2010; 24: 1781-4
Roper J, Richardson MP, Wang WV, et al. Richard LG, The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One. 2011;6(9):e25132
Sacco A, Roccaro AM, Ghobrial I, Role of dual PI3/Akt and mTOR inhibition in Waldenstrom macroglobulinemia. Oncotarget 2010; 1: 578-582.
Roccaro AM, Sacco A, Husu EN, et al., Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood. 2010; 115: 559-69.
Chou TC and Talalay P, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22 :27-55.
Witzig TE, Gupta M, Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program. 2010; 2010: 265-70.
Bhatt AP, Bhende PM, Sin SH, et al., Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR addicted lymphoma. Blood 2010; 115: 4455-4463.
Chiarini F, Grimaldi C, Ricci F, et al., Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res. 2010: 15; 70: 8097-107.
Coiffier B, Ribrag V. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Leuk Lymphoma. 2009 Dec;50(12):1916-30.
National Institutes of Health (NIH). ClinicalTrials.gov. http://www.clinicaltrial.gov/ct2/show/NCT01283516?term=LDK378&rank=1. Updated January 24, 2011. Accessed January 26, 2011.
Janakiram M, Thirukonda VK, Sullivan M, et al., Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma. Curr Treat Options Oncol. 2012 [Epub ahead of print]
Ma S, Rosen ST. Enzastaurin. Curr Opin Oncol. 2007; 19 (6): 590-5.
Civallero M, Cosenza M, Grisendi G, et al., Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. Leuk Lymphoma. 2010; 51: 671-9.
Liu J, Kuo WL, Seiwert T, et al., Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck 2011; 33: 1774-82.
Nyfeler B, Chen Y, Li X, et al. RAD001 enhances the potency of BEZ235 to inhibit mTOR signalling and tumor growth. PLOS one 2012; 7: 1-9.
Hideshima T, Catley L, Yasui H, et al.: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, 107:4053–4062.
Leleu X, Jia X, Runnels J, et al, , The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007; 110: 4417-26.
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)